Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy.

BACKGROUND AND PURPOSE To evaluate the impact of ATR inhibition using AZD6738 in combination with radiotherapy on the response of non-small cell lung cancer (NSCLC) tumour models and a murine model of radiation induced fibrosis. MATERIALS AND METHODS AZD6738 was evaluated as a monotherapy and in combination with radiation in vitro and in vivo using A549 and H460 NSCLC models. Radiation induced pulmonary fibrosis was evaluated by cone beam computed tomography (CBCT) and histological staining. RESULTS AZD6738 specifically inhibits ATR kinase and enhanced radiobiological response in NSCLC models but not in human bronchial epithelial cells (HBECs) in vitro. Significant tumour growth delay was observed in cell line derived xenografts (CDXs) of H460 cells (p<0.05) which were less significant in A549 cells. Combination of AZD6738 with radiotherapy showed no significant change in lung tissue density by CBCT (p>0.5) and histological scoring of radiation induced fibrosis (p>0.5). CONCLUSION Inhibition of ATR with AZD6738 in combination with radiotherapy increases tumour growth delay without observable augmentation of late radiation induced toxicity further underpinning translation towards clinical evaluation in NSCLC.

[1]  D. de Ruysscher,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  K. Harrington,et al.  The hallmarks of cancer and the radiation oncologist: updating the 5Rs of radiobiology. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[3]  Isabel L Jackson,et al.  Revisiting Strain-Related Differences in Radiation Sensitivity of the Mouse Lung: Recognizing and Avoiding the Confounding Effects of Pleural Effusions , 2010, Radiation research.

[4]  E. Hammond,et al.  Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  J. Nissink,et al.  Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer. , 2015, Future medicinal chemistry.

[6]  Borivoj Vojnovic,et al.  SMALL ANIMAL IGRT SPECIAL FEATURE : COMMENTARY Implications of respiratory motion for small animal image-guided radiotherapy , 2016 .

[7]  T. Conrads,et al.  The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo , 2015, Oncotarget.

[8]  A. Ryan,et al.  ATM and ATR as therapeutic targets in cancer. , 2015, Pharmacology & therapeutics.

[9]  B. Cornelissen,et al.  Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation , 2012, Cell Death and Disease.

[10]  W. Mckenna,et al.  Targeting radiation-resistant hypoxic tumour cells through ATR inhibition , 2012, British Journal of Cancer.

[11]  O. Fernandez-Capetillo,et al.  Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. , 2012, The Journal of clinical investigation.

[12]  S. Bhide,et al.  Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei , 2016, Molecular Cancer Therapeutics.

[13]  Carlos Ortiz-de-Solorzano,et al.  Longitudinal study of a mouse model of chronic pulmonary inflammation using breath hold gated micro-CT , 2010, European Radiology.

[14]  Richard A. Adams,et al.  Clinical development of new drug–radiotherapy combinations , 2016, Nature Reviews Clinical Oncology.

[15]  S. Elledge,et al.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. , 2000, Genes & development.

[16]  J. Fowler,et al.  Repair in mouse lung for up to 20 fractions of X rays or neutrons. , 1985, The British journal of radiology.

[17]  M. Tomayko,et al.  Determination of subcutaneous tumor size in athymic (nude) mice , 2004, Cancer Chemotherapy and Pharmacology.

[18]  J. Fowler,et al.  Repair in mouse lung of multifraction X rays and neutrons: extension to 40 fractions. , 1985, The British journal of radiology.

[19]  M Oudkerk,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Andrea Bezjak,et al.  Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.

[21]  L. Karnitz,et al.  Molecular Pathways: Targeting ATR in Cancer Therapy , 2015, Clinical Cancer Research.

[22]  T. Puck,et al.  ACTION OF X-RAYS ON MAMMALIAN CELLS , 1956, The Journal of experimental medicine.

[23]  J. Masson,et al.  DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer , 2015, Biomolecules.

[24]  Frank Verhaegen,et al.  A longitudinal evaluation of partial lung irradiation in mice by using a dedicated image-guided small animal irradiator. , 2014, International journal of radiation oncology, biology, physics.

[25]  Judith A. Goodship,et al.  A splicing mutation affecting expression of ataxia–telangiectasia and Rad3–related protein (ATR) results in Seckel syndrome , 2003, Nature Genetics.

[26]  A. Ashworth,et al.  The potential of exploiting DNA-repair defects for optimizing lung cancer treatment , 2012, Nature Reviews Clinical Oncology.

[27]  K. Cimprich,et al.  ATR: an essential regulator of genome integrity , 2008, Nature Reviews Molecular Cell Biology.

[28]  H. Bolte,et al.  Standardized quantification of pulmonary fibrosis in histological samples. , 2008, BioTechniques.

[29]  J. Sarkaria,et al.  Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. , 1999, Cancer research.

[30]  L. Zou,et al.  DNA damage sensing by the ATM and ATR kinases. , 2013, Cold Spring Harbor perspectives in biology.

[31]  M. Dewhirst,et al.  Linking the History of Radiation Biology to the Hallmarks of Cancer , 2014, Radiation research.

[32]  J. Bates,et al.  Measuring the lung function in the mouse: the challenge of size , 2003, Respiratory research.

[33]  C. Faivre-Finn,et al.  The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

[34]  Nicolai J. Birkbak,et al.  Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[35]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.